PAI-1 Gene as a Target for Breast Cancer Therapy
Abstract
The purpose of the work in year Ol of this study was to generate stable lines of human breast carcinoma cells which expressed varying levels of plasminogen activator inhibitor type-1 (PAl-1) as a consequence of transfection with a vector bearing a PAT-1 cDNA insert under control of MYC-responsive E box sequences. A panel of 14 such genetically-engineered cells was developed which varied significantly in the level of vector-driven PAT-1 mRNA and protein expression. Two of these cell lines were assessed as to their ability to adhere to the extracellular matrix protein vitronectin. High level PAT-1 synthesizing transfectants were significantly impaired compared to parental control breast carcinoma cells with regard to their adhesive ability. A comprehensive characterization of the growth traits of these cells, as well as the continuing generation of new estrogen-dependent transfectants will be completed in year 02.
Document Details
- Document Type
- Technical Report
- Publication Date
- Apr 01, 1999
- Accession Number
- ADA388123
Entities
People
- Paul J. Higgins
Organizations
- Albany Medical College